Search

Displaying results 971 - 980 of 6831 in total
  1. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    [L31453] Ivermectin is mainly used in humans in the treatment of onchocerciasis, but may also be effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis … [L36763,A238929] In addition, the use of aggregate patient data in large-scale meta-analyses (as opposed to individual patient data (IPD)) has been shown to disguise otherwise blatant data errors, such

    Mixtures: Heartgard Plus Chewable Tablet for Dogs - Up to 25 lbs
  2. Drug

    Levofloxacin

    go.drugbank.com/drugs/DB01137
    ApprovedInvestigational

    [A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663] … (i.e. it does not invert to the inactive isomer).

  3. Indication

    Adenosine Deaminase Deficiency

    go.drugbank.com/conditions/DBCOND0051206
    Drugs: Pegademase
    Synonyms: Severe combined immunodeficiency due to adenosine deaminase deficiency
  4. Indication

    Neuroborreliosis, Borrelia Burgdorferi

    go.drugbank.com/conditions/DBCOND0078182
    Drugs: Ceftriaxone
    Synonyms: Infection due to Borrelia burgdorferi sensu lato
  5. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the

  6. Indication

    Glycogen Storage Disease Type II

    go.drugbank.com/conditions/DBCOND0002595
    Drugs: Alglucosidase alfa · Avalglucosidase alfa
    Synonyms: Glycogenosis due to acid maltase deficiency, Glycogen storage disease due to acid maltase deficiency (disorder)
  7. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the

  8. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.

  9. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].

  10. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621] … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.